Lake Street raised the firm’s price target on Cellebrite (CLBT) to $23 from $22 and keeps a Buy rating on the shares. The firm was “pleased to see Cellebrite get back on track” following what it calls out as “two consecutive quarters of disappointment.” The firm, which raised its 2025 estimates, tells investors that the strength in U.S. state and local and LATAM have it “feeling more confident the business is back on the right track.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLBT:
- Cellebrite price target raised to $25 from $24 at BofA
- Cellebrite price target raised to $24 from $23 at JPMorgan
- Cellebrite DI: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating
- Cellebrite DI Positioned for Growth: Buy Rating Affirmed Amid Federal Demand Recovery and Strategic Alignments
- Cellebrite Reports Strong Q3 2025 Financial Results